Free · no account · quoted from the filing

What changed in RVMD's 10-Q

Source: 10-Q filed 2026-05-06 · compared against 10-Q 2025-11-05. Every passage below is quoted verbatim from the filing itself.

Pipeline

This filing

RASolute 302, RASolute 303, RASolute 304, RASolute 305, and RASolve 301

Regulatory

This filing

we intend to submit the data from the topline readout of RASolute 302 to the FDA as part of a future NDA under a CNPV

Accounting Standards

This filing

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270), Narrow-Scope Improvements.

Risk Factors

This filing

If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of any approved products.

What it means — the analyst reading

The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel, plus 2 further changes without a quotable passage — is part of the Filing Change Monitor.

See the Filing Change Monitor →

Compared from narrative excerpts (outlook, risks, MD&A) of both filings — quotes are verbatim from the new filing. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.